Investigating	0	13	O
the	14	17	O
causes	18	24	O
of	25	27	O
low	28	31	O
birth	32	37	O
weight	38	44	O
in	45	47	O
contrasting	48	59	O
ovine	60	65	O
paradigms	66	75	O
.	75	76	O

Intrauterine	78	90	O
growth	91	97	O
restriction	98	109	O
(	110	111	O
IUGR	111	115	O
)	115	116	O
still	117	122	O
accounts	123	131	O
for	132	135	O
a	136	137	O
large	138	143	O
incidence	144	153	O
of	154	156	O
infant	157	163	B-Organism
mortality	164	173	O
and	174	177	O
morbidity	178	187	O
worldwide	188	197	O
.	197	198	O

Many	199	203	O
of	204	206	O
the	207	210	O
circulatory	211	222	O
and	223	226	O
transport	227	236	O
properties	237	247	O
of	248	250	O
the	251	254	O
sheep	255	260	B-Organism
placenta	261	269	B-Organ
are	270	273	O
similar	274	281	O
to	282	284	O
those	285	290	O
of	291	293	O
the	294	297	O
human	298	303	B-Organism
placenta	304	312	B-Organ
and	313	316	O
as	317	319	O
such	320	324	O
,	324	325	O
the	326	329	O
pregnant	330	338	O
sheep	339	344	B-Organism
offers	345	351	O
an	352	354	O
excellent	355	364	O
model	365	370	O
in	371	373	O
which	374	379	O
to	380	382	O
study	383	388	O
the	389	392	O
development	393	404	O
of	405	407	O
IUGR	408	412	O
.	412	413	O

Two	414	417	O
natural	418	425	O
models	426	432	O
of	433	435	O
ovine	436	441	O
IUGR	442	446	O
are	447	450	O
those	451	456	O
of	457	459	O
hyperthermic	460	472	O
exposure	473	481	O
during	482	488	O
pregnancy	489	498	O
,	498	499	O
and	500	503	O
adolescent	504	514	O
overfeeding	515	526	O
,	526	527	O
also	528	532	O
during	533	539	O
pregnancy	540	549	O
.	549	550	O

Both	551	555	O
models	556	562	O
yield	563	568	O
significantly	569	582	O
reduced	583	590	O
placental	591	600	B-Organ
weights	601	608	O
and	609	612	O
an	613	615	O
asymmetrically	616	630	O
growth	631	637	O
-	637	638	O
restricted	638	648	O
fetus	649	654	B-Developing_anatomical_structure
,	654	655	O
and	656	659	O
display	660	667	O
altered	668	675	O
maternal	676	684	O
hormone	685	692	O
concentrations	693	707	O
,	707	708	O
indicative	709	719	O
of	720	722	O
an	723	725	O
impaired	726	734	O
trophoblast	735	746	B-Cell
capacity	747	755	O
.	755	756	O

Additionally	757	769	O
,	769	770	O
impaired	771	779	O
placental	780	789	B-Organ
angiogenesis	790	802	O
and	803	806	O
uteroplacental	807	821	B-Organism_substance
blood	822	827	I-Organism_substance
flow	828	832	O
appears	833	840	O
to	841	843	O
be	844	846	O
an	847	849	O
early	850	855	O
defect	856	862	O
in	863	865	O
both	866	870	O
the	871	874	O
hyperthermic	875	887	O
and	888	891	O
adolescent	892	902	O
paradigms	903	912	O
.	912	913	O

The	914	917	O
effects	918	925	O
of	926	928	O
these	929	934	O
alterations	935	946	O
in	947	949	O
placental	950	959	B-Organ
functional	960	970	O
development	971	982	O
appear	983	989	O
to	990	992	O
be	993	995	O
irreversible	996	1008	O
.	1008	1009	O

IUGR	1010	1014	O
fetuses	1015	1022	B-Developing_anatomical_structure
are	1023	1026	O
both	1027	1031	O
hypoxic	1032	1039	O
and	1040	1043	O
hypoglycaemic	1044	1057	O
,	1057	1058	O
and	1059	1062	O
have	1063	1067	O
reduced	1068	1075	O
insulin	1076	1083	B-Gene_or_gene_product
and	1084	1087	O
insulin	1088	1095	B-Gene_or_gene_product
-	1095	1096	I-Gene_or_gene_product
like	1096	1100	I-Gene_or_gene_product
growth	1101	1107	I-Gene_or_gene_product
factor	1108	1114	I-Gene_or_gene_product
-	1114	1115	I-Gene_or_gene_product
1	1115	1116	I-Gene_or_gene_product
(	1117	1118	O
IGF	1118	1121	B-Gene_or_gene_product
-	1121	1122	I-Gene_or_gene_product
1	1122	1123	I-Gene_or_gene_product
)	1123	1124	O
,	1124	1125	O
and	1126	1129	O
elevated	1130	1138	O
concentrations	1139	1153	O
of	1154	1156	O
lactate	1157	1164	B-Drug_or_compound
.	1164	1165	O

However	1166	1173	O
,	1173	1174	O
fetal	1175	1180	O
utilization	1181	1192	O
of	1193	1195	O
oxygen	1196	1202	B-Drug_or_compound
and	1203	1206	O
glucose	1207	1214	B-Drug_or_compound
,	1214	1215	O
on	1216	1218	O
a	1219	1220	O
weight	1221	1227	O
basis	1228	1233	O
,	1233	1234	O
remain	1235	1241	O
constant	1242	1250	O
compared	1251	1259	O
with	1260	1264	O
control	1265	1272	O
pregnancies	1273	1284	O
.	1284	1285	O

Maintained	1286	1296	O
utilization	1297	1308	O
of	1309	1311	O
these	1312	1317	O
substrates	1318	1328	O
,	1328	1329	O
in	1330	1332	O
a	1333	1334	O
substrate	1335	1344	O
-	1344	1345	O
deficient	1345	1354	O
environment	1355	1366	O
,	1366	1367	O
suggests	1368	1376	O
increased	1377	1386	O
sensitivities	1387	1400	O
to	1401	1403	O
metabolic	1404	1413	O
signals	1414	1421	O
,	1421	1422	O
which	1423	1428	O
may	1429	1432	O
play	1433	1437	O
a	1438	1439	O
role	1440	1444	O
in	1445	1447	O
the	1448	1451	O
development	1452	1463	O
of	1464	1466	O
metabolic	1467	1476	O
diseases	1477	1485	O
in	1486	1488	O
later	1489	1494	O
adult	1495	1500	O
life	1501	1505	O
.	1505	1506	O

